Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC. Materials and Methods Patients with locally advanced or metastatic nccRCC, except for collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cycle was defined as 4 weeks and tumor response was evaluated every two cycles. The primary objective was overall response rate (ORR). Results A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment- related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay. Conclusion In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.
Abstract
Purpose The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC. Materials and Methods Patients with locally advanced or metastatic nccRCC, except for collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cycle was defined as 4 weeks and tumor response was evaluated every two cycles. The primary objective was overall response rate (ORR). Results A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment- related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay. Conclusion In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.
참고문헌 (26)
- Leibovich BC, "Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma", J Urol, 183, pp.1309~1315 (2010)[DOI]
- Motzer RJ, "Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology", J Clin Oncol, 20, pp.2376~2381 (2002)[DOI]
- Vera-Badillo FE, "Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis", Eur Urol, 67, pp.740~749 (2015)[DOI]
- [URL]
- Dutcher JP, "Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies", Med Oncol, 26, pp.202~209 (2009)[DOI]
- Hudes G, "Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma", N Engl J Med, 356, pp.2271~2281 (2007)[DOI]
- Heng DY, "Anti-angiogenic targets in the treatment of advanced renal cell carcinoma", Curr Cancer Drug Targets, 8, pp.676~682 (2008)[DOI]
- Rini BI, "Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma", Cancer, 115(10 Suppl), pp.2306~2312 (2009)[DOI]
- Sternberg CN, "Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial", J Clin Oncol, 28, pp.1061~1068 (2010)[DOI]
- Sternberg CN, "A randomised, double-blind phase III study of pazopanib in patients with advanced and", or metastatic renal cell carcinoma: final overall survival results and safety update, 2013, pp.49, 1287~1296
- Motzer RJ, "Pazopanib versus sunitinib in metastatic renal-cell carcinoma", N Engl J Med, 369, pp.722~731 (2013)[DOI]
- Altorki N, "Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I", II resectable non-small-cell lung cancer, 2010, pp.28, 3131~3137
- Friedlander M, "A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer", Gynecol Oncol, 119, pp.32~37 (2010)[DOI]
- van der Graaf WT, "Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 379, pp.1879~1886 (2012)[DOI]
- Gore ME, "Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma", Br J Cancer, 113, pp.12~19 (2015)[DOI]
- Choueiri TK, "Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma", J Clin Oncol, 26, pp.127~131 (2008)[DOI]
- Lee JL, "Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma", Ann Oncol, 23, pp.2108~2114 (2012)[DOI]
- Matrana MR, "Outcomes of patients with metastatic nonclear-cell renal cell carcinoma treated with pazopanib", Clin Genitourin Cancer, 15, pp.e205~e208 (2017)[DOI]
- Motzer RJ, "Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma", J Clin Oncol, 17, pp.2530~2540 (1999)[DOI]
- Koh Y, "Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma", Ann Oncol, 24, pp.1026~1031 (2013)[DOI]
- Gordon MS, "Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317", J Clin Oncol, 27, pp.5788~5793 (2009)[DOI]
- Armstrong AJ, "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial", Lancet Oncol, 17, pp.378~388 (2016)[DOI]
- Sankin A, "Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies", Front Oncol, 5, pp.67~ (2015)
- Tannir NM, "A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma", Eur Urol, 62, pp.1013~1019 (2012)[DOI]
- Necchi A, "Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial", Lancet Oncol, 13, pp.810~816 (2012)[DOI]
- Qi WX, "Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis", Crit Rev Oncol Hematol, 89, pp.394~403 (2014)[DOI]